Ahmedabad-based Zydus gets USFDA approval to market generic acne drug

A combination of Adapalene (a retinoid) and Benzoyl Peroxide (an antibiotic and skin-peeling agent), the gel is used to decrease the number and severity of acne pimples

Zydus Lifesciences
Press Trust of India New Delhi
2 min read Last Updated : Jun 07 2022 | 4:15 PM IST

Zydus Lifesciences on Tuesday said it has received final approval from the US health regulator to market Adapalene and Benzoyl Peroxide topical gel, used to treat acne, in the American market.

The drug firm has received final approval from the US Food and Drug Administration (USFDA) to market the product, it said in a statement.

A combination of Adapalene (a retinoid) and Benzoyl Peroxide (an antibiotic and skin-peeling agent), the gel is used to decrease the number and severity of acne pimples.

Adapalene works by affecting the growth of cells and decreasing swelling and inflammation, and Benzoyl Peroxide works by reducing the amount of acne-causing bacteria and by causing the skin to dry and peel off.

The drug will be manufactured at the group's topical facility at Ahmedabad, Zydus Lifesciences noted.

As per IQVIA MAT April 22 data, Adapalene and Benzoyl Peroxide Topical Gel had a market size of USD 195 million in the US.

Zydus Group now has 315 approvals and has so far filed over 420 abbreviated new drug applications (ANDAs) since the commencement of the filing process in FY 2003-04, the drug firm said.

Shares of the drug firm were trading 2.28 per cent down at Rs 356.35 apiece on the BSE.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Zydus LifesciencesUSFDAskincare

First Published: Jun 07 2022 | 4:15 PM IST

Next Story